FDA Approves Enlicitide, First Oral PCSK9 Pill, After 56% LDL Reduction in 24 Weeks
Updated
Updated · Medscape · Jul 23
FDA Approves Enlicitide, First Oral PCSK9 Pill, After 56% LDL Reduction in 24 Weeks
3 articles · Updated · Medscape · Jul 23
Summary
Enlicitide won FDA clearance as the first once-daily oral PCSK9 inhibitor for hypercholesterolemia, including heterozygous familial hypercholesterolemia, giving patients a non-injectable alternative to existing PCSK9 drugs.
Two trials drove the approval: CORALreef Lipids showed a 56% LDL reduction versus placebo at 24 weeks, while CORALreef HeFH showed a 59% reduction in adults with familial hypercholesterolemia.
At $315 for a 30-day supply, the pill could broaden use in primary care, where prior research found more than 95% of primary care physicians and nearly 40% of cardiologists had not prescribed a PCSK9 inhibitor as of 2022.
Its real-world impact is still uncertain because patients must take it each morning on an empty stomach and wait 30 minutes before eating, raising adherence questions that injectables partly avoid.
Outcome trials on heart attacks and other cardiovascular events are still underway, even as experts say LDL lowering appears comparable to injectable PCSK9 antibodies and inclisiran.
With competitors developing unrestricted alternatives, will this first-of-its-kind oral PCSK9 inhibitor become obsolete before it transforms primary care?
Can this groundbreaking daily pill actually prevent heart attacks, or is it just another way to manipulate cholesterol numbers?
Will the strict morning fasting rules of this new cholesterol pill secretly sabotage the very patients trying to avoid needles?
Lipfendra (Enlicitide) 2026: First Oral PCSK9 Inhibitor Approved by FDA—Clinical Efficacy, Safety, and Market Implications
Overview
Lipfendra (enlicitide), approved by the FDA in July 2026 as the first oral PCSK9 inhibitor, marks a major advance in cholesterol management. Merck engineered enlicitide as a daily tablet, combining it with sodium caprate to help the drug pass through the gut wall and achieve oral bioavailability. Once absorbed, enlicitide blocks PCSK9 from binding to LDL receptors, allowing more receptors to clear LDL cholesterol from the blood. Clinical trials showed dramatic LDL-C reductions of up to 65%, outperforming other oral therapies and matching injectables, while offering a needle-free, convenient option that improves patient adherence and access.